Human Immunology Biosciences launches with $120M to target immune cells directly

Human Immunology Biosciences is a clinical-stage biotech developing precision-targeted drugs for autoimmune and inflammatory diseases, built around a toolkit that uses genetic biomarkers and computational data to identify drug targets.

Targeting the specific immune cells that drive autoimmune disease, like plasma cells, instead of broad suppression, would treat disease without the infection tradeoff.

Human Immunology Biosciences was started in 2021, built by biotech studios Monograph Capital and ARCH Venture Partners to pursue precision-targeted treatment for autoimmune and inflammatory disease.

The San Francisco-based company emerged from stealth in November 2022 with $120M in funding and two drug candidates, including felzartamab, targeting plasma cells considered likely drivers of autoimmune and inflammatory disease. It entered a crowded field — Crunchbase data showed more than $2B invested in immune-system drug startups like Rheos Medicines and Mast Therapeutics in 2022 alone — betting its target-identification toolkit, built on genetic biomarkers and computational data, would differentiate its pipeline.

Existing autoimmune drugs broadly suppress the immune system, creating an infection-risk tradeoff that a more targeted approach could avoid

Advances in genomics and computational biology made it newly feasible to identify precise cellular targets rather than treating the immune system as a single system to suppress

Backing from two established biotech studios and a $120M stealth-exit round signaled investor conviction it could compete in a category that had already drawn over $2B in 2022 funding

In a crowded, well-funded therapeutic category, a company can differentiate less on the disease it targets than on the precision of the method it uses to find drug targets within that disease.

As of 2022-11-02, Human Immunology Biosciences had just emerged from stealth with $120M and two drug candidates, including felzartamab, still in its pipeline rather than in approved use.